

1 July 2024

Scancell Holdings plc
("Scancell" or the "Company")

Block Listing Return and Total Voting Rights

Change of Name of Nominated Adviser and Joint Broker

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for the treatment of cancer, announces that it has allotted and issued a further 620,000 new ordinary shares of £0.001 each ("Ordinary Shares"), pursuant to its block listing facility, in satisfaction of the exercise of share options granted under the Company's existing options plan.

Following this issue, there will be a total of 929,599,977 Ordinary Shares in issue. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure and Transparency Rules.

Block Listing Return

The Company makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:

Name of applicant:	Scancell Holdings plc		
Number and class of securities originally admitted:	2,880,000 ordinary shares of £0.001 each		
Date of admission:	17 April 2023		
Period of return:	From:	17 October 2023	To: 30 June 2024
Balance of unallotted securities under scheme(s) from previous return:	620,000		
<u>Plus:</u> The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):	0		
<u>Less:</u> Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):	620,000		
<u>Equals:</u> Balance under scheme(s) not yet issued/allotted at end of period:	0		
Total number of securities in issue at the end of the period	929,599,977		

Change of Name of Nominated Adviser and Joint Broker

The Company also announces that its Nominated Adviser and Joint Broker has changed its name to Panmure Liberum Limited following completion of its own corporate merger.

For further information, please contact:

Scancell Holdings plc

Professor Lindy Durrant, CEO
Dr Jean-Michel Cosséry, Non-Executive Chairman

+44 (0) 20 3709 5700

Panmure Liberum Limited (Nominated Advisor and Joint Broker)
Emma Earl, Freddy Crosslet, Will Goode, Mark Rogers (Corporate Finance)
Rupert Dearden (Corporate Broking)

+44 (0) 20 7886 2500

WG Partners LLP (Joint Broker)

David Wilson/Claes Spang/Satheesh Nadarajah/Erland Stemby

+44 (0) 20 3705 9330

ICR Consilium

Mary-Jane Elliott/Angela Gray/Lindsey Neville

+44 (0) 20 3709 5700

scancell@consilium-comms.com

About Scancell

Scancell is a clinical stage biopharmaceutical company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer and infectious disease. The Company is building a pipeline of innovative products by utilising its four technology platforms: Moditope® and ImmunoBody® for vaccines and GlyMab® and AvidiMab® for antibodies.

Adaptive immune responses include antibodies and T cells (CD4 and CD8), both of which can recognise damaged or infected cells. In order to destroy such cancerous or infected cells, Scancell uses either vaccines to induce immune responses or monoclonal antibodies (mAbs) to redirect immune cells or drugs. The Company's unique approach is that its innovative products target modifications of proteins and lipids. For the vaccines (Moditope® and ImmunoBody®) this includes citrullination and homocitrullination of proteins, whereas its mAb portfolio targets glycans or sugars that are added onto proteins and / or lipids (GlyMab®) or enhances the potency of antibodies and their ability to directly kill tumour cells (AvidiMab®).

For further information about Scancell, please visit: <https://www.scancell.co.uk/>

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCDZGFVNGVGDZM